News

Cystic Fibrosis Canada acknowledges a new significant step forward in access to the life-changing cystic fibrosis drug Trikafta.

Cystic Fibrosis Canada receives funding from Canada's Drug Agency to continue strengthening the Canadian Cystic Fibrosis Registry  

October 21, 2024 – Today, we were pleased to receive nearly $200,000 in funding from Canada’s Drug Agency (CDA) as part of their efforts to strengthen rare disease registries in Canada. 

Our commitment at Cystic Fibrosis Canada to ensure everyone with cystic fibrosis (CF) can live W/O Limits is more vital than ever!

Cystic Fibrosis Canada is encouraged by a recent decision by Health Canada to approve the life-changing cystic fibrosis (CF) drug Trikafta for some living with rare mutations that lead to CF.

Génome Québec and Cystic Fibrosis Canada announce the launch of the Tackle Rare, Orphan CFTR Mutations Competition to support research on rare mutations for which no treatment is available, with the long-term goal of developing novel therapies.

Cystic Fibrosis Canada has opened its annual grant competition for 2024. Canadian researchers with an interest in cystic fibrosis (CF), including its connection to diabetes and cancer, can now apply for funding to be awarded starting in early 2025.

Progress has been made towards improving access to the life-changing cystic fibrosis (CF) medication, Trikafta, in Canada.

CF Canada successfully hosted the virtual CF Canada Community Forum: "Unchartered Territories" on April 26, 2024. If you couldn’t make it to CF Canada’s Community Forum “Unchartered Territories" last week, CF Canada has you covered!

It is with great pleasure that Génome Québec and Cystic Fibrosis Canada join forces to create a new funding program to support omics research on cystic fibrosis.

 The team at Cystic Fibrosis Canada is pleased to share our 2023-24 Impact Report.